In one of the newly published investigations in the magazine JAMAData for about 1.5 million people were investigated and it was found that in people with diabetes who take drugs such as samglytide or throat, the risk of opaque nerve disorders increased.
The study specifically refers to a rare but destructive disease called “aerior aerior neuropathic neuropathic neuropathy” (Naion). The disease causes the bloodstream to the optic nerve to decrease or block, which can lead to an eye stroke. Paties usually notice the disease when they have lost their eyesight. The importa thing is that treatme has not been known for this disease so far.
Earlier, a study showed that every 6,000 people are likely to develop naion due to Samgotide consumption. But in a rece study, out of the 6,000 paties with type 2 diabetes who received samaglotide or tirepathids, 4 people (ie about one out of every 2 people) were infected with Naion.
During two years of follow -up, the researchers ideified 3 cases of NaION in the consumer consumer group of Samglotide or Tirzepatide. Also, the other 5 paties had various optic nerve disorders.
Another large study conducted on 6,000 people published in the same magazine found that GLP-RA weight loss drugs were associated with an increased risk of diabetic retinopathy (damage to retinal blood vessels).
However, the researchers emphasized that participas who took GLP-1 drugs had less threatening visual complications than those who received diabetes and had less need for invasive eye treatmes.
Although the overall risk of such low diseases is assessed, the researchers have recommended that paties be more accurate. They also called for further long -term research to clarify how these drugs affect eye health.
(tagstotranslate) Scieific research
